Characteristics of Magnifying Endoscopy with Narrow Band Imaging Findings in Gastric Cancer after <italic>Helicobacter pylori</italic> Eradication.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: chronic atrophic gastritis
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
pylori eradication is being widely used in chronic atrophic gastritis cases. Therefore, the diagnosis of post-eradication gastric cancer using ME-NBI is expected to gain importance in daily clinical practice.
[BACKGROUND] Helicobacter pylori (H.
APA
Horiuchi Y, Yamamoto N (2025). Characteristics of Magnifying Endoscopy with Narrow Band Imaging Findings in Gastric Cancer after Helicobacter pylori Eradication.. Digestion, 1-10. https://doi.org/10.1159/000547574
MLA
Horiuchi Y, et al.. "Characteristics of Magnifying Endoscopy with Narrow Band Imaging Findings in Gastric Cancer after Helicobacter pylori Eradication.." Digestion, 2025, pp. 1-10.
PMID
40695251 ↗
Abstract 한글 요약
[BACKGROUND] Helicobacter pylori (H. pylori) eradication reduces the risk of gastric cancer development and is effective in patients with chronic atrophic gastritis. Recently, an increase in gastric cancer incidence has been observed in daily clinical practice in patients who have undergone H. pylori eradication. Therefore, continuous surveillance endoscopy is important for detecting gastric cancer after H. pylori eradication. In addition, endoscopic findings may differ between non-eradication and post-eradication gastric cancer. Magnifying endoscopy with narrow band imaging (ME-NBI) has been useful for the diagnosis of post-eradication gastric cancer, regardless of the histological type. However, there have been no comprehensive reports in this regard. Here, we aimed to clarify the characteristics of ME-NBI findings in gastric cancer following H. pylori eradication.
[SUMMARY] In differentiated- and mixed-type cancers (a mixture of differentiated and undifferentiated type), the cancer may be covered by noncancerous epithelium following H. pylori eradication; however, abnormalities can still be detected using ME-NBI. Therefore, ME-NBI is suitable for the diagnosis of post-eradication gastric cancer. In undifferentiated-type cancer, ME-NBI is more useful in diagnosing post-eradication gastric cancer than non-eradicated gastric cancer because of the clear contrast between cancerous and noncancerous areas following eradication. In addition, when non-eradicated gastric cancer is detected, rather than performing endoscopic submucosal dissection (ESD) or gastrectomy without eradication, it is beneficial to start patients on eradication therapy immediately and diagnose the disease extent with ME-NBI without awaiting the results of the eradication assessment and performing ESD or gastrectomy. This approach is expected to prevent misdiagnosis of the tumor size and reduce the positivity of the horizontal margin in ESD or gastrectomy.
[KEY MESSAGES] The number of post-eradication gastric cancer cases is expected to increase in comparison to non-eradicated gastric cancer cases, as H. pylori eradication is being widely used in chronic atrophic gastritis cases. Therefore, the diagnosis of post-eradication gastric cancer using ME-NBI is expected to gain importance in daily clinical practice.
[SUMMARY] In differentiated- and mixed-type cancers (a mixture of differentiated and undifferentiated type), the cancer may be covered by noncancerous epithelium following H. pylori eradication; however, abnormalities can still be detected using ME-NBI. Therefore, ME-NBI is suitable for the diagnosis of post-eradication gastric cancer. In undifferentiated-type cancer, ME-NBI is more useful in diagnosing post-eradication gastric cancer than non-eradicated gastric cancer because of the clear contrast between cancerous and noncancerous areas following eradication. In addition, when non-eradicated gastric cancer is detected, rather than performing endoscopic submucosal dissection (ESD) or gastrectomy without eradication, it is beneficial to start patients on eradication therapy immediately and diagnose the disease extent with ME-NBI without awaiting the results of the eradication assessment and performing ESD or gastrectomy. This approach is expected to prevent misdiagnosis of the tumor size and reduce the positivity of the horizontal margin in ESD or gastrectomy.
[KEY MESSAGES] The number of post-eradication gastric cancer cases is expected to increase in comparison to non-eradicated gastric cancer cases, as H. pylori eradication is being widely used in chronic atrophic gastritis cases. Therefore, the diagnosis of post-eradication gastric cancer using ME-NBI is expected to gain importance in daily clinical practice.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in -amplified gastric cancer.
- Association of preoperative frailty and prognostic nutritional index with postoperative delirium in elderly gastric cancer patients: A single-center observational study.
- Treating a single tumor deposits as two lymph node metastases can improve the accuracy of gastric cancer prognosis assessment.
- Complete response to Nivolumab-based chemotherapy in a case of advanced gastric cancer with multiple immune-related adverse events.
- Apatinib and silver nanoparticles synergize against gastric cancer through the PI3K/Akt signaling pathway-mediated ferroptosis.